Aug 19, 2021
NCT05014646: Phase 2: Leflunomide for High-Risk Smoldering MM in African-Am. & European-Am. Patients
NCT05014646: Phase 2: Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American...
178
Dec 11, 2020
NCT04508790: Phase 2: Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of RRMM Myeloma
NCT04508790: Phase 2: Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma...
55